EVENTS · LLY
PEERS
EARNINGS
No company news, with general drug manufacturers higher as a group
Eli Lilly and Company is a global medicine company focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Eli Lilly and Company operates across major therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular care, serving patients, healthcare providers, and health systems worldwide. Its current portfolio includes widely used treatments for chronic metabolic conditions as well as therapies for cancer and immune-related diseases, supported by ongoing commercial operations and regulated manufacturing capacity in the United States, Europe, and Asia. The company also advances diagnostics and specialty medicines that address complex medical needs in hospital, outpatient, and community settings. Eli Lilly and Company plays a significant role in the pharmaceutical market through its broad product lineup, large-scale distribution network, and focus on prescription medicines that are used in everyday clinical practice.
| Series | 1W | 1M |
|---|---|---|
| LLY | +10.1% | +22.5% |
| Peers | +6.7% | +13.5% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 82 | 93 |
| Series | 1W | 1M |
|---|---|---|
| LLY | +10.1% | +22.5% |
| Peers | +6.7% | +13.5% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 82 | 93 |
